Thank you for you time and research. I agree the
Post# of 22456
I agree the main agreement between QDX HealthID is for the distribution of QDX HealthID by Innova in the USA.
Based on my post yesterday that I reposted from Bige1960, Innova owns Biotime. Biotime contracted with Covidsignals for distribution of test kits.
Do you not think that Innova could tell Biotime to tell Covidsignals to use QDX HealthID on all it's test kits? If it's good for Innova why wouldn't it be good for their subsidiaries?
I speculate that thanks to QMC's international contacts for QDX HealthID, these same contacts have needs for tests also. Why wouldn't Covidsignals or Biotime or Innova not pay a fee to QMC for every test sale that QDX HealthID facilitates?
I believe test manufacturers are signing up with QDX HealthID because they realize both their need for it and the specific advantages, which includes ID management and anticounterfeiting and the flexibility to scale easily.
We still do not know the pricing model, so I speculate that there is a charge when a test is used, and a recurring monthly SaaS charge because repeat tests will be needed by the testee. There is speculation based on a comment by QMC they get $2/test, but it has not been verified. Multiply that by millions of tests and whew!
QMC can offer two other products to Covid-19 rapid test manufacturers specifically. Biotime uses gold nanorods and QMC can make gold nanocrystals which give superior performance. Even an increase from 98% to 99% makes s big difference in test results.
Another product in conjunction with QDX HealthID is anticounterfeiting test kits. Labeling test kits with QD make them incredibly secure against being faked.
It's all speculation but it's all more than possible. QDX HealthID can be QMC's entre to it's other products and services for test manufacturers. I see multiple income streams.